FDA Alerts

FDA
FDA
FDA Approves First Methotrexate Oral Solution
04/26/2017
The FDA has approved Xatmep, an oral solution for the treatment of acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.
04/26/2017
Lipids
Lipids
FDA Approves New Dosing Option for Praluent
04/25/2017
The FDA has approved a new, monthly dosing option for the PCSK9-inhibitor Praluent (alirocumab).
04/25/2017
Treatment
Treatment
FDA: New Indication for Thymoglobulin
04/24/2017
The FDA has approved a new indication for the drug Thymoglobulin, for use in patients undergoing kidney transplant.
04/24/2017
FDA
FDA
New Biosimilar Approved by the FDA
04/24/2017
The US Food and Drug Administration recently approved the second biosimilar to Remicade for the treatment of immune-disorders.
04/24/2017
bladder
bladder
FDA Approves New First-Line Bladder Cancer Treatment
04/18/2017
The FDA has approved the first and only cancer immunotherapy for the initial treatment of certain bladder cancers.
04/18/2017
Diabetic Retinopathy
Diabetic Retinopathy
FDA Approves New Treatment for Diabetic Retinopathy
04/17/2017
The FDA has approved the first and only option for the treatment of all forms of diabetic retinopathy.
04/17/2017
Movement Disorders
Movement Disorders
FDA Approves First Drug to Treat Tardive Dyskinesia
04/12/2017
The US Food and Drug Administration has approved a new capsule for the treatment of the neurological disorder tardive dyskinesia.
04/12/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017
Movement Disorders
Movement Disorders
FDA Approves Austedo for Treatment of Huntington Disease-Associated Chorea
04/04/2017
The US Food and Drug Administration has approved Austedo (deutetrabenazine) tablets for the treatment of chorea in patients with Huntington disease.
04/04/2017
FDA
FDA
FDA Expands Indication for Metastatic Breast Cancer Treatment
04/03/2017
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
04/03/2017